When a Tender Demands 75 Percent or 80 Percent Remaining Shelf Life on a Sterile Device: Why FDA April 1991 and EU MDR GSPR 11.4 Do Not Set a Remaining-Percentage Statute, Why UNICEF October 2023 Uses Two Thirds and a Five-Year Floor, Why WHO TRS 1044 Annex 8 Is a Months Table After Risk Assessment, and Why ISO 11607 Is Not the Dock Clock

International medical-device procurement managers, hospital biomedical engineers, and specialized distributors routinely encounter incoming tender specifications mandating that sterile consumables retain 75 percent, 80 percent, or 18 months of remaining shelf life upon physical arrival at the receiving warehouse dock. When maritime transits or customs delays leave an inbound lot below that copied percentage, receiving departments often threaten rejection as if the consignment violated FDA, EU MDR or ISO 11607. This guide separates those instruments. By reading FDA April 1991, 21 CFR 801.18, EU MDR Annex I GSPR 6, 7, 11.4 and 23.2, UNICEF's current October 2023 medical-device technical requirements, WHO TRS 1044 Annex 8, and the WHO specification-corpus census, it gives distributors and OEM sellers a remaining-life RFQ matrix instead of another aging-method HOW file.

Table of contents

• Does FDA April 1991 or 21 CFR 801.18 set a remaining-percentage-at-delivery rule for medical devices?
• What do EU MDR GSPR 6, 7, 11.4 and 23.2(i) require, and why is that not 75 percent remaining at import?
• What does UNICEF October 2023 actually print for total shelf life and remaining life at delivery?
• What is WHO TRS 1044 Annex 8, and why is Appendix 1 a months table after risk assessment rather than a 75 percent law?
• The WHO medical device procurement specification corpus: 4,070 rows and zero remaining-percentage mandates
• Does ISO 11607-1, ASTM F1980, or Rec 14-594 set remaining life at the dock?
• Why do tenders copy 75 percent, 80 percent, 18 months or two thirds?
• Worked examples across VEMERIX SKUs, and why NOVACURE is out of scope
• Distributor and OEM RFQ checklist
• Where VEMERIX fits—and where due diligence still begins
• Frequently asked questions

Does FDA April 1991 or 21 CFR 801.18 set a remaining-percentage-at-delivery rule for medical devices?

A pervasive myth in international procurement is that the United States Food and Drug Administration (FDA) mandates a minimum remaining shelf life—frequently asserted as 75% or 80%—when medical devices enter commercial distribution or arrive at a healthcare facility. This assumption conflates premarket device stability validation with postmarket commercial purchasing contracts. The primary regulatory foundation for expiration dating under US law derives from the FDA Center for Devices and Radiological Health (CDRH) guidance document titled Shelf Life of Medical Devices, issued in April 1991 (with content confirmed current by FDA as of March 27, 2018) ¹, ².

The April 1991 guidance informs medical-device manufacturers how to establish, scientifically justify, and document a device's shelf life and expiration date. In the guidance text, FDA defines shelf life as 'the term or period during which a commodity remains suitable for the intended use' and defines expiration date as 'the termination of shelf life, after which a percentage of the commodity, e.g., medical devices, may no longer function as intended' ². The document outlines stability-testing considerations and recognizes that some simple devices (such as tongue depressors) may not need a labelled shelf life because the likelihood of time-dependent degradation and the seriousness of failure are both low ¹. Nowhere in that guidance does FDA set a remaining-percentage-at-delivery rule for importation, wholesale transfer, or hospital receiving.

Similarly, federal labeling regulations under 21 CFR 801.18 (Format of dates provided on a medical device label) ³ govern only the typographical format of printed dates on device labels and packages. The UDI final rule added this section: whenever a medical device label includes a printed expiration date, date of manufacture, or any other date intended to be brought to the attention of the user, the date must be presented as four-digit year, two-digit month and two-digit day, separated by hyphens (for example, 2014-01-02) ³. The printed exceptions are a combination product that properly bears a National Drug Code (NDC) number, and an electronic product whose date of manufacture is presented under 21 CFR 1010.3(a)(2)(ii). Neither exception is a remaining-percentage dock test, and 801.18 does not require every device to carry an expiration date. A use-by symbol on artwork is a separate label-clock from remaining months at a named Incoterms point; see ISO 15223-1 EU REP symbol acceptance after 17 June 2026. Federal device law does not prohibit distribution, sale or use of a sterile device solely because remaining shelf life has fallen below 75 or 80 percent, provided the labelled expiration date has not passed, the sterile barrier remains intact, and storage has followed the manufacturer's labelled conditions.

What do EU MDR GSPR 6, 7, 11.4 and 23.2(i) require, and why is that not 75 percent remaining at import?

In the European Union, the regulatory regime under Regulation (EU) 2017/745 on medical devices (EU MDR) ⁴ addresses device lifetime, packaging integrity, and labeling through the General Safety and Performance Requirements (GSPR) set out in Annex I. Just as with US FDA regulations, European economic operators frequently encounter tender clauses or port-of-entry customs demands claiming that the EU MDR mandates a 75% or 80% remaining shelf life upon physical import into the Union. An examination of the statutory legal text of Annex I proves that no such percentage requirement exists under European Union law.

The governing GSPR articles operate on functional safety and barrier integrity rather than commercial percentage clocks: ⁴

• GSPR 6 (Lifetime and Maintenance): Requires that the characteristics and performance of a device must not be adversely affected to such a degree that the health or safety of the patient or user and of other persons are compromised during the lifetime of the device, as indicated by the manufacturer, when the device is subjected to the stresses which can occur during normal conditions of use and has been properly maintained in accordance with the manufacturer's instructions.
• GSPR 7 (Transport and Storage Design): Dictates that devices must be designed, manufactured, and packaged in such a way that their characteristics and performances during their intended use are not adversely affected during transport and storage conditions (for example, fluctuations of temperature and humidity) taking into account the instructions and information provided by the manufacturer.
• GSPR 11.4 (Sterile Packaging Integrity Until Point of Use): Explicitly establishes the legal performance threshold for terminally sterilized medical devices: 'Devices delivered in a sterile state shall be designed, manufactured and packaged in accordance with appropriate procedures, to ensure that they are sterile when placed on the market and that, unless the packaging which is intended to maintain their sterile condition is damaged, they remain sterile, under the transport and storage conditions specified by the manufacturer, until that packaging is opened at the point of use.'
• GSPR 23.2(i) and 23.2(j) (time limit and date of manufacture): The label must bear 'an unambiguous indication of the time limit for using or implanting the device safely, expressed at least in terms of year and month, where this is relevant'. Where there is no indication of the date until when the device may be used safely, GSPR 23.2(j) requires the date of manufacture. A separate particular, GSPR 23.2(k), requires an indication of any special storage and/or handling condition. None of those label particulars sets 75 percent remaining at import.

EU MDR GSPR 11.4 establishes a binary physical performance test: the device remains sterile and functional until the packaging is opened at the point of use, provided the sterile barrier is undamaged and storage conditions have complied with the manufacturer's instructions ⁴. Notified Bodies audit the manufacturer's Technical Documentation—specifically the stability studies conducted under ISO 11607-1 and ISO 11607-2 packaging validation, aging and lot-release tests—to confirm that the sterile barrier and device components maintain their specification until the year and month indicated under GSPR 23.2(i). Neither GSPR 11.4, the European Commission's MDCG guidance documents, nor EU customs legislation establishes a 75% remaining shelf life clock at import. An EU distributor or hospital that refuses a shipment on the grounds that MDR requires 75% remaining shelf life is confusing an internal institutional procurement rule with a European Union statutory mandate.

What does UNICEF October 2023 actually print for total shelf life and remaining life at delivery?

If remaining shelf life percentages are absent from US and European device statutes, where did the international procurement habit of demanding a fractional remaining life originate? The most influential institutional source in global health procurement is the United Nations Children's Fund (UNICEF) Supply Division. The live UNICEF medical-devices technical-requirements landing ⁶ currently posts Technical Requirements for Medical Devices (MD) — Generic, October 2023 ⁵. That current file—not the January 2019 predecessor ¹⁷—is the UNICEF MD term a supplier should quote in September 2026.

Under Section 5 (Product shelf life / life span), UNICEF October 2023 prints three interconnected operational requirements: ⁵

• Minimum total shelf life floor: 'Products with a shelf life of less than 5 years are normally not acceptable; however, in special circumstances UNICEF may accept shorter shelf life.' The January 2019 predecessor used a 36-month floor; the current October 2023 file raised that usual floor to five years.
• The two-thirds remaining rule: 'The supplier shall ensure that two thirds of the shelf life remain at delivery unless specifically authorised in writing by UNICEF prior to delivery.'
• Remedy for non-compliance: 'Any product delivered with less than two thirds remaining shelf life, shall be rejected by UNICEF, at no cost to UNICEF. The supplier shall be responsible for and bear the costs for returning the goods.'

The mathematical reality of UNICEF's remaining-life clause is immediately apparent: two thirds is about 66.7 percent, not 75 percent and not 80 percent. UNICEF also prints that two-thirds remaining rule for neighbouring commodity families: the Technical Requirements for In Vitro Diagnostics (IVD, November 2021) ⁷ and for Personal Protective Equipment (PPE, April 2022) ⁸. Those IVD and PPE files do not copy the MD five-year total-shelf-life floor. In UNICEF's operational framework, the two-thirds buffer is a buyer contract term complete with a written-deviation mechanism. When commercial distributors copy 'two thirds'—or inflate it to 75 or 80 percent—into a private hospital RFQ, they transform UNICEF's logistics buffer into an arbitrary trade barrier. Pasting the January 2019 36-month floor into a 2026 UNICEF MD bid is equally stale: the current usual floor is five years.

What is WHO TRS 1044 Annex 8, and why is Appendix 1 a months table after risk assessment rather than a 75 percent law?

The second major international reference frequently cited in tender disputes is the World Health Organization (WHO) Technical Report Series No. 1044 (published in 2022). Annex 8 of TRS 1044 is titled Points to consider for setting the remaining shelf-life of medical products upon delivery ⁹, ¹⁰. Developed under the auspices of the WHO Expert Committee on Specifications for Pharmaceutical Preparations, this guidance represents a landmark attempt to harmonize remaining-shelf-life principles across international humanitarian agencies, donor organizations, and recipient governments.

Significantly, TRS 1044 Annex 8 extends remaining-life principles beyond finished pharmaceuticals. The introduction records that the document 'should cover not only finished pharmaceutical products but should be extended to cover other products, including medical devices, vaccines and in vitro diagnostics (IVD) products,' collectively referred to as medical products ⁹. The glossary defines remaining shelf-life as 'the period remaining from the date of delivery to the expiry date, retest date, install-by date or other use-before date established by the manufacturer' ⁹. Instead of a 75 or 80 percent formula, Section 5.1 requires remaining life to be defined realistically after a documented risk assessment that considers product type, inventory, manufacturing and transit lead time, local release, storage, the delivery chain, and resources in the recipient country.

Appendix 1 of TRS 1044 Annex 8 is an example table of minimum remaining shelf-life, in absolute months, at three named handoff points after risk assessment: ¹⁰

• 48 months < TSL ≤ 60 months: 40 months remaining at dispatch from the manufacturer's premises; 30 months at delivery at port of entry; 12 months at end-user level.
• 36 months < TSL ≤ 48 months: 30 months at manufacturer dispatch; 24 months at port of entry; 12 months at end user.
• 24 months < TSL ≤ 36 months: 20 months at manufacturer dispatch; 15 months at port of entry; 6 months at end user.
• 12 months < TSL ≤ 24 months: 9 months at manufacturer dispatch; 7 months at port of entry; 3 months at end user.
• TSL ≤ 12 months: special arrangements and conditions apply.

Three principles follow from the live table ¹⁰. First, the cells are absolute months, not fixed percentages. For a device in the 48 months < TSL ≤ 60 months band, 30 months remaining at port of entry is 50 percent or less of labelled life—below the 75 or 80 percent often claimed by buyers. Second, remaining life is stage-dependent: manufacturer dispatch, port of entry, and end user are different clocks. Third, Appendix 1 is an example. Section 5.1 states that remaining-life or expiry-date responsibilities should be covered in agreements between suppliers, purchasers and recipients ⁹. WHO also recommends that national policy consider the document; that recommendation still does not convert Appendix 1 into an FDA or EU remaining-percentage statute.

The WHO medical device procurement specification corpus: 4,070 rows and zero remaining-percentage mandates

To determine whether international health authorities incorporate remaining-shelf-life percentages into standardized medical-device procurement specifications, an empirical census was conducted across the World Health Organization's official medical-device technical specifications corpus ¹². The analyzed dataset, drawn from the comprehensive August 26, 2026 snapshot, encompasses 4,070 standardized specification field rows covering 74 unique medical devices and priority life-saving commodities (spanning the WHO 61-device core technical workbook and 13 priority maternal, newborn, and surgical commodities).

The census counted every Shelf life (if relevant) cell across those 74 device records. The findings are: ¹²

• Universality of the Field: The standardized specification field label 'Shelf life (if relevant)' appears on 100% of the device specification sheets (all 74 unique devices).
• Unpopulated or Not-Applicable Cells (65 Devices): In 65 out of 74 devices (87.8%), the field is either left blank, designated 'N/A', or refers to general durability, reflecting the fact that capital equipment, surgical instruments, diagnostic hardware, and non-perishable consumables do not degrade under shelf aging.
• Populated Total Shelf Life / Useful Life Cells (9 Devices): Only 9 device specifications populate the field with specific temporal parameters: capital equipment like diagnostic spirometers, floor scales, fetal heart monitors, and electrosurgical diathermy units populate the field with an expected service life of '10 years'; portable mechanical ventilators record 'Variable'; female condoms specify a claimed total shelf life of 'not less than 3 years and not more than 7 years'; and single-use injection syringes (re-use prevention / RUP and non-RUP syringes) and suction catheters include standard stability notes indicating that empirical evidence typically supports shelf lives up to 5 years.
• Remaining-Percentage-at-Delivery Mandates (Zero Devices): Across the entire corpus of 4,070 field rows and 74 medical devices, exactly zero devices (0.0%) contain a specification requiring a remaining shelf life percentage (such as 75% or 80%) upon delivery.

That specification-sheet finding is consistent with WHO's current Invitation-to-Bid / Request-for-Quotation technical-requirements document (Version 5, January 2026) ¹⁸. In the pharmaceutical shelf-life section, WHO states that at purchase-order stage, unless authorised in writing in advance, the TRS 1044 Annex 8 remaining-life guidance applies. In the medical-devices document list, the same file asks for ISO 13485 or ISO 9001, ISO 10993 biocompatibility, ISO 14971 risk assessment, and sterility/stability standards such as ISO 11135 and ISO 11137. It does not copy the Appendix 1 remaining-percentage or months table into those device sheets. Remaining life at a named delivery point therefore remains an exceptional, commodity-specific contract term unless the buyer has actually written UNICEF two thirds, WHO Appendix 1 months, or its own clause into the RFQ.

Does ISO 11607-1, ASTM F1980, or Rec 14-594 set remaining life at the dock?

A frequent point of friction during incoming receiving inspections occurs when hospital procurement officers cite packaging validation standards—most notably ISO 11607-1:2019 ¹¹, ASTM F1980 (accelerated aging), or FDA Recognized Consensus Standards—as technical justification for demanding 80% remaining shelf life. In fact, this site's own historical commercial guidance (such as the bulk-price FAQ in the landed-cost, MOQ and short-dated-stock gates for a circumcision-device bulk order) previously noted that international buyers commonly demand an 80% remaining shelf life buffer while referencing ISO 11607. From an engineering and regulatory perspective, that association is an internal misattribution that must be clearly dismantled.

ISO 11607-1:2019 (Packaging for terminally sterilized medical devices — Part 1: Requirements for materials, sterile barrier systems and packaging systems) ¹¹ governs the physical, chemical, and microbiological integrity of sterile packaging. Its scope is explicitly defined: to establish requirements and test methods for materials, preformed sterile barrier systems, and packaging systems that are intended to maintain sterility of terminally sterilized medical devices until the point of use. Under ISO 11607-1, a sterile barrier system is validated through rigorous empirical testing: sterile barrier seal integrity (ASTM F88 peel testing, ASTM F1929 dye penetration), microbial barrier properties, transit simulation (ASTM D4169), and real-time and accelerated aging (ASTM F1980) ¹¹. If a sterile barrier system demonstrates valid seal strength and barrier integrity at the 3-year or 5-year aging timepoint, the packaging complies with ISO 11607-1 throughout every single day of that validated period.

Nothing in ISO 11607-1, ISO 11607-2 (process validation), or ASTM F1980 establishes a dock clock, a warehouse velocity rule, or an incoming-inspection percentage threshold. A blister pack that arrives at a hospital with 6 months of remaining shelf life on a 3-year validated expiry has the exact same sterile barrier integrity as one that arrives with 28 months of remaining shelf life, assuming storage temperatures and transport conditions have remained within validated limits. Furthermore, as detailed in our analysis of which ISO 11607 packaging declaration of conformity survives 20 December 2026, FDA Recognized Consensus Standards (such as Rec 14-594 for ISO 11607-1:2019/Amd 1:2023 versus the transitional Rec 14-530) represent premarket regulatory declaration windows for 510(k) submissions, not dock clocks that render warehouse lots illegal when a tender percentage is breached. Waving an ISO 11607 Declaration of Conformity (DoC) does not prove that a device meets an 80% remaining-life tender clause, and missing an 80% tender clause does not indicate non-compliance with ISO 11607.

Why do tenders copy 75 percent, 80 percent, 18 months or two thirds, and which neighbouring commodity each number actually belongs to?

If remaining shelf life percentages are not medical device statutes, why do hospital tenders, defense procurement RFQs, and national health tenders across the Middle East, Southeast Asia, Latin America, and Africa uniformly demand 75%, 80%, 18 months, or two thirds? The answer lies in institutional procurement history and the widespread practice of tender template copying. Hospital tender committees rarely draft procurement specifications from scratch; instead, administrative staff borrow language from neighboring commodity contracts, institutional donor templates, or legacy pharmacy guidelines. Tracing these specific numbers to their true origins clarifies why they are misapplied to sterile single-use devices.

Each widely copied tender metric originates from a specific regulatory or commercial sector: ⁵, ⁹

• The 80 percent metric (short-dated IVD reagents and diagnostic kits): Hospital and national tenders often copy an 80 percent remaining-life buffer used for short-dated liquid reagents, controls and diagnostic kits. That neighbouring-commodity practice is not a sterile-device statute, and it is not printed in FDA April 1991, 21 CFR 801.18, MDR GSPR 11.4, UNICEF MD October 2023, or WHO TRS 1044 Appendix 1. Copying it onto a circumcision blister or stapler treats biochemical reagent decay as if it were polymer or metal hardware aging.
• The 75 Percent Metric (Pharmaceutical Wholesaling & GMP Distribution): The '75% remaining shelf life' standard is a commercial convention originating in wholesale pharmaceutical distribution. Active pharmaceutical ingredients (APIs) and finished solid-dose drugs (tablets, capsules) distributed across retail pharmacy chains typically carry a 3-year (36-month) or 5-year (60-month) shelf life. Wholesalers demand 75% remaining life upon receipt to ensure sufficient time for inventory rotation, warehousing, pharmacy shelf display, and patient consumption before expiry. It is a commercial inventory-turnover covenant, not a statutory medical device regulation.
• The 18 months metric (emergency health kits): WHO TRS 1044 Annex 8 Appendix 2 is an example table for emergency health kits, not a hospital receiving statute ¹⁰. For kits with 24 months < TSL ≤ 36 months, the example is 18 months remaining at dispatch from the supplier's premises, 15 months at port of entry, and 6 months at the end user. It is not a universal 18-month remaining-life rule at kit assembly for scheduled hospital device orders.
• The two-thirds (~66.7 percent) metric (UNICEF medical devices): This is the authentic UNICEF contract term, retained from January 2019 ¹⁷ into October 2023 ⁵. October 2023 also raised the usual MD total-shelf-life floor from 36 months to five years. Two thirds remains UNICEF's remaining-life fraction; it is not FDA or EU law.
• Hospital 'Event-Related Sterility' Conflation: In hospital Central Sterile Supply Departments (CSSD), reusable surgical instruments wrapped in CSR wrap or placed in rigid containers follow the clinical doctrine of 'event-related sterility'—sterility is compromised by handling events, moisture, or tears rather than time. Receiving staff sometimes conflate hospital CSSD policies with industrial terminal sterilization, creating confusion over whether expiration dates represent time-related decay or event-related boundaries.

Worked examples: a CE-marked EO circumcision blister versus an NMPA-only sterile needle versus a 24-month cooling-spray TSL versus an SKU with no public shelf-life spec, and why NOVACURE is out of scope

To understand how remaining shelf life clauses apply in commercial practice, procurement teams must evaluate devices against their specific regulatory registrations, sterilization modalities, packaging configurations, and stability dossiers. Weihai Medison Medical Equipment Co., Ltd. (the manufacturer behind the international brand VEMERIX) produces a diverse portfolio spanning urology consumables, aesthetic delivery devices, and perioperative wound products. Evaluating five representative products against an incoming 75% or 80% tender clause demonstrates the essential contract-versus-statute distinctions.

The portfolio analysis reveals distinct technical pathways: ¹³, ¹⁴, ¹⁵, ¹⁶

• Scenario A — VEMERIX Circumcision Device (CE-Marked EO Blister SKU): The Circumcision Device is an NMPA Class II registered (Lu Mech Reg. 20172020238) and CE-marked sterile single-use circumcision ring available in Adult and Children types ¹³. It is sterilized via ethylene oxide (EO) and packaged in individual sterile blister packs. If an international distributor signs an RFQ specifying delivery under Incoterms CIF Port of Entry with an 80% remaining shelf life clause on a 3-year (36-month) validated shelf life, the device must arrive at the port with at least 28.8 months remaining. If maritime shipping delays cause the shipment to arrive with 26 months remaining (~72%), the shipment does NOT violate EU MDR GSPR 11.4 or CE mark validity; however, it technically breaches the commercial contract term. The distributor's remedy is commercial negotiation (e.g., price discount, shelf-life extension addendum, or expedited hospital turnover plan) rather than regulatory rejection.
• Scenario B — Disposable Circumcision Stapler (Factory EO Sterilized, NMPA Only): The Disposable Circumcision Stapler is an NMPA Class II device (Lu Mech Reg. 20192020192) indicated for one-pass cut and staple anastomosis ¹⁴. Unlike the circumcision ring, public product data records Factory EO sterilization without a CE mark. When bidding this SKU in non-EU tenders (e.g., Southeast Asia or Central Asia), buyers must evaluate remaining shelf life solely against the manufacturer's NMPA stability dossier and the named contract. A distributor cannot demand compliance with EU MDR GSPR 11.4 or invent a CE-marked shelf-life certification.
• Scenario C — Sterile Single-Use Injection Needle (NMPA Class III sterile SKU): The Sterile Single-Use Injection Needle is registered under NMPA Class III for clinical and aesthetic injection workflows ¹⁵. Public product data record no CE mark. For China-bound hospital supply, remaining life at delivery follows the named purchasing contract and the labelled expiry on the registered lot. Imposing UNICEF's two-thirds clause, or FDA Rec 14-594 packaging-DoC language, on that NMPA Class III needle order is the wrong instrument unless UNICEF is the buyer or a US packaging DoC is actually in the file.
• Scenario D — Cooling Spray (24-month total shelf life contrast): The Cooling Spray is a topical 60 g water-based burn and scald hydrogel ¹⁶. Public product data record a labelled total shelf life of 24 months. Two boundary conditions follow. First, 24 months is below UNICEF's current five-year usual MD floor ⁵ and was already below the January 2019 36-month floor ¹⁷; a UNICEF MD bid would need written authorisation for the shorter life. Second, an 80 percent remaining clause on a 24-month TSL leaves only 4.8 months of elapsed time from manufacture to the named delivery point. WHO TRS 1044 Appendix 1 places 12 months < TSL ≤ 24 months at 9 / 7 / 3 months remaining (dispatch / port / end user), not the 15-month port cell that belongs to the 24 months < TSL ≤ 36 months band. Negotiate an absolute-month number at the named Incoterms point rather than copying 80 percent.
• Scenario E — Medical Laser Fiber & Capital Console Boundary: Medison's NMPA-registered single-use medical laser fiber (Lu Mech Reg. 20192010517) is sterile, individually packed, and pairs with a partner-supplied diode laser source for 1470 nm endovenous varicose-vein workflows. Public product data does not list a fixed shelf-life duration; buyers must request the current batch expiration date directly from the factory rather than assuming a default 5-year expiry. Furthermore, the partner-supplied NOVACURE Semiconductor Laser Treatment System (Guangdong Yunshang, NMPA Class III) is a capital equipment console, not a sterile consumable. Consoles undergo preventive maintenance and calibration rather than expiration dating, rendering remaining-shelf-life dock clauses completely inapplicable.

Distributor and OEM RFQ checklist: named delivery point, labelled expiry, remaining months or fraction, UNICEF two thirds versus WHO Appendix 1 months versus a buyer-specific clause, and the documents to request

When negotiating international supply contracts, private-label manufacturing agreements, or distribution tenders, distributors and OEM buyers must avoid passive acceptance of vague 'standard shelf life' clauses. To protect commercial margins, prevent dock rejections, and maintain regulatory compliance, procurement teams should execute a systematic six-step verification audit for every sterile device lot.

1. Step 1 — Establish the Empirical Total Shelf Life (TSL): Demand the manufacturer's formal shelf-life justification dossier. Verify whether the labelled expiration date is supported by real-time stability data, accelerated aging protocols (ASTM F1980), or intermediate testing. Confirm that the total shelf life is printed clearly on outer cartons and primary blister labels in compliance with 21 CFR 801.18 (YYYY-MM-DD) ³ or EU MDR GSPR 23.2(i) (YYYY-MM) ⁴.
2. Step 2 — Define the Exact Named Delivery Point (Incoterms 2020): A remaining-shelf-life percentage is meaningless without a geographically defined delivery point. Does 75% remaining apply when the goods leave the factory floor (Ex Works), when loaded on board (FOB), when cleared through customs at the destination port (CIF / DPU), or when received at the hospital receiving dock (DDP)? Ensure the contract links the shelf-life calculation to the agreed Incoterms point to protect against maritime shipping delays.
3. Step 3 — Convert Percentages into Absolute Months: Percentages create operational ambiguity. For a 24-month product, 80% remaining allows only 4.8 months of elapsed time; for a 60-month product, 80% allows 12 months. Convert tender percentages into an agreed minimum number of months at delivery, using WHO TRS 1044 Annex 8 Appendix 1 ¹⁰ as an objective reference framework.
4. Step 4 — Differentiate UNICEF contracts from commercial tenders: If the procurement contract is issued by UNICEF Supply Division, use the current October 2023 MD file: usual total shelf life of at least 5 years, and two thirds remaining at delivery, or prior written authorisation ⁵. Do not quote the superseded January 2019 36-month floor as if it were still the posted MD term. If UNICEF is not the buyer, treat two thirds as a copied contract option, not a statute.
5. Step 5 — Separate ISO 11607 Barrier Evidence from Supply-Chain Clocks: Require the manufacturer's ISO 11607-1 Declaration of Conformity and packaging validation summary ¹¹ to confirm sterile barrier integrity. Cross-check sterilization batch release records against ISO 11135 ethylene-oxide cycle validation acceptance and confirm residual safety under which ISO 10993-7 edition still governs an EO residual CoA. Do not accept an ISO 11607 certificate as proof of remaining delivery days, and do not allow receiving inspectors to reject valid sterile barriers based on misquoted packaging standards.
6. Step 6 — Establish a Contractual Buffer & Short-Dated Stock Protocol: Formulate an explicit contractual clause defining the remedies if an inbound shipment arrives with less than the target remaining life due to logistical delays. Standard remedies include a tiered price discount, guaranteed distributor swap-out provisions, or an expedited consumption schedule coordinated with clinical departments.

Where VEMERIX fits—and where due diligence still begins

VEMERIX is the international brand of Weihai Medison Medical Equipment Co., Ltd., positioned as a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery, and perioperative care. In the international supply of sterile single-use surgical consumables, VEMERIX operates on a philosophy of transparent technical disclosure and rigorous compliance with empirical regulatory standards.

For international distributors, procurement agencies, and private-label OEM partners evaluating surgical tenders, VEMERIX provides comprehensive technical dossiers supporting our flagship consumables: ¹³, ¹⁴

• Empirical stability documentation: The CE-marked Circumcision Device can be discussed against labelled expiry, ISO 11607 packaging validation and ISO 11135 ethylene-oxide cycle files. The Disposable Circumcision Stapler is a separate Factory-EO NMPA SKU; public product data do not record a CE mark or a remaining-life SLA.
• Batch traceability and labelling: Buyers should request batch-specific Certificates of Analysis recording sterilization date, lot number and labelled expiry, and should check that printed dates match the format required by the destination market.
• Contractual clarity on delivery terms: Remaining months at a named Incoterms point are negotiated lot by lot. VEMERIX does not publish a blanket remaining-life SLA and does not issue an '80 percent statutory compliance' certificate.

However, due diligence still begins with the buyer. VEMERIX does not issue fictitious '80% statutory compliance certificates', nor do we claim that international device regulations enforce an arbitrary dock clock. We do not manufacture or claim ownership of partner-supplied consoles such as the NOVACURE laser system, and we do not broaden CE indications to products registered solely under NMPA. When preparing an international tender, procurement teams should review our validated technical files, examine our quality and regulatory certifications, and contact our engineering team via VEMERIX International Sourcing to establish tailored, defensible delivery specifications.

Frequently asked questions

Is there a US remaining-shelf-life percentage statute for medical devices on 11 September 2026?

No. There is no US federal statute, regulation, or FDA guidance setting a mandatory remaining-shelf-life percentage at importation, commercial delivery, or hospital receiving. FDA's April 1991 guidance (Shelf Life of Medical Devices) ¹, ² establishes how manufacturers determine and justify expiration dates based on empirical stability data. 21 CFR 801.18 ³ mandates the YYYY-MM-DD typographical format when dates appear on labels, but it does not govern inventory aging or dock receiving percentages. Any 75% or 80% requirement in the US is strictly a private commercial purchasing covenant.

Does EU MDR GSPR 11.4 require 75 percent remaining shelf life at import?

No. EU MDR 2017/745 Annex I GSPR 11.4 ⁴ requires that devices delivered in a sterile state remain sterile until the packaging is opened at the point of use, provided the packaging is undamaged and storage conditions comply with the manufacturer's instructions. GSPR 23.2(i) requires an unambiguous indication of the time limit for safe use (year and month). Neither the MDR nor European customs regulations establish a 75% or 80% remaining-shelf-life import threshold.

If UNICEF is not the buyer, can a distributor still paste two thirds into every RFQ?

A distributor can write any mutually agreed term into a private commercial contract, but copying UNICEF's two-thirds clause into a private tender does not make it an international regulatory requirement. UNICEF's current October 2023 Technical Requirements for Medical Devices ⁵ enforce two thirds remaining life and normally a five-year total shelf life for UNICEF-funded MD procurement. The January 2019 file ¹⁷ is the historical predecessor that used a 36-month floor. Applying either UNICEF edition to a private hospital order without mutual agreement creates an artificial trade barrier, not a US or EU violation.

Does WHO TRS 1044 Annex 8 bind a private hospital tender?

No. WHO Technical Report Series documents provide normative, technical guidance for Member States, donor organizations, and public health authorities ⁹. TRS 1044 Annex 8 provides a rational framework and an illustrative months table (Appendix 1) to assist parties in structuring remaining-shelf-life agreements following risk assessment. It explicitly states that remaining-shelf-life terms must be formally agreed upon and written into contracts. It has no statutory force unless incorporated into national law or private contracts.

Does ISO 11607-1:2019 set remaining life at the dock?

No. ISO 11607-1:2019 ¹¹ specifies physical, chemical, and integrity requirements for sterile barrier materials and packaging systems to maintain sterility until the point of use. It contains no clauses governing commercial distribution speed, transit buffers, or dock acceptance percentages. Packaging that complies with ISO 11607 maintains its validated sterile barrier integrity until its labelled expiration date, regardless of whether it arrives with 80% or 20% remaining life.

If a lot is already on a distributor shelf, does missing a tender remaining-life percentage make that lot illegal?

No. Missing a tender remaining-shelf-life percentage is a breach of a commercial purchasing contract, not a violation of device safety laws. A legally cleared or CE-marked medical device stored under validated conditions remains fully legal to distribute, sell, and use right up until its printed expiration date. A hospital tender rejection does not render the inventory illegal or adulterated.

Does the 20 December 2026 Rec 14-530 packaging-DoC clock change remaining shelf life?

No. As explained in our guide on which ISO 11607 packaging declaration of conformity survives 20 December 2026, the December 20, 2026 transition from FDA Rec 14-530 to Rec 14-594 is a regulatory declaration-of-conformity window for premarket 510(k) submissions. It governs premarket regulatory paperwork, not the commercial remaining shelf life of distributed warehouse lots.

Does VEMERIX already publish a remaining-life SLA for these SKUs?

VEMERIX does not publish a blanket remaining-shelf-life Service Level Agreement (SLA) across all SKUs. Remaining months at a named Incoterms point depend on production scheduling, order volume and destination geography, and are negotiated lot by lot. Buyers should request the current labelled expiry and the batch Certificate of Analysis rather than assume an 80 percent statutory certificate.